Identification of the molecular subtype and prognostic characteristics of lung adenocarcinoma based on CD8+ T cell-related gene signature.

IF 1.9 4区 医学 Q3 ONCOLOGY
Cancer Biomarkers Pub Date : 2024-12-01 Epub Date: 2025-03-17 DOI:10.1177/18758592241296764
Keke Tang, Ji Shen, Dan Liu, Jia Che, Qifen Mao, Yixuan Zhou, Hainan Ye
{"title":"Identification of the molecular subtype and prognostic characteristics of lung adenocarcinoma based on CD8<sup>+</sup> T cell-related gene signature.","authors":"Keke Tang, Ji Shen, Dan Liu, Jia Che, Qifen Mao, Yixuan Zhou, Hainan Ye","doi":"10.1177/18758592241296764","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundLung adenocarcinoma (LUAD) stands as a major respiratory malignancy with high mortality. With the advent of immunotherapy, new therapeutic avenues have emerged in cancer treatment.ObjectiveOur focus aimed at developing a CD8<sup>+</sup> T cell-based immune gene prognostic model (CDIGPM) for LUAD, shedding light on the immunological aspects and the potential advantages of immunotherapy in distinct CDIGPM-defined LUAD categories.MethodsData from LUAD patients were extracted from the TCGA and GEO databases (GSE11969). The differentially expressed genes (DEGs) were intersected with immune genes from ImmPort and InnateDB, yielding 89 significant immune genes related to CD8<sup>+</sup> T cells (CDIGs). Univariate Cox regression and LASSO regression analyses were performed on 10 hub CDIGs (ADM, CAV1, CTSL, HLA-DMB, HLA-DQA1, IGHM, PLSCR1, PTGDS, S100A16, and WFDC2). Furthermore, the immunological attributes and the immunotherapy efficacy in CDIGPM-defined categories were explored. Moreover, to support the findings of the bioinformatics analysis, fifteen LUAD patients' tumor and adjacent tissues were collected for qRT-PCR detection of CDIGPM-related genes.ResultsKaplan-Meier analysis revealed that the high-CDIGPM group exhibited significantly poorer overall survival (OS) trajectories, whereas the low-CDIGPM group showed more favorable OS trajectories, indicating a better prognosis. Age, tumor stage, and CDIGPM score were identified as independent prognostic factors. The high-CDIGPM group was enriched in pathways related to the cell cycle, focal adhesion, and cancer, while the low-CDIGPM group was associated with immune response-related pathways. The CDIGPM model effectively differentiated clinical subtypes in patients with LUAD. QRT-PCR detection of Clinical LUAD samples also validated the differentially expression of CDIGPM model related genes.ConclusionsThe study highlights the prognostic importance of CDIGs in LUAD using the CDIGPM model, linking age, stage and CDIGPM score to poor outcomes. The identified genes and pathways provide potential therapeutic targets, deepening our understanding of LUAD's molecular landscape.</p>","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":"41 3-4","pages":"18758592241296764"},"PeriodicalIF":1.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/18758592241296764","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

BackgroundLung adenocarcinoma (LUAD) stands as a major respiratory malignancy with high mortality. With the advent of immunotherapy, new therapeutic avenues have emerged in cancer treatment.ObjectiveOur focus aimed at developing a CD8+ T cell-based immune gene prognostic model (CDIGPM) for LUAD, shedding light on the immunological aspects and the potential advantages of immunotherapy in distinct CDIGPM-defined LUAD categories.MethodsData from LUAD patients were extracted from the TCGA and GEO databases (GSE11969). The differentially expressed genes (DEGs) were intersected with immune genes from ImmPort and InnateDB, yielding 89 significant immune genes related to CD8+ T cells (CDIGs). Univariate Cox regression and LASSO regression analyses were performed on 10 hub CDIGs (ADM, CAV1, CTSL, HLA-DMB, HLA-DQA1, IGHM, PLSCR1, PTGDS, S100A16, and WFDC2). Furthermore, the immunological attributes and the immunotherapy efficacy in CDIGPM-defined categories were explored. Moreover, to support the findings of the bioinformatics analysis, fifteen LUAD patients' tumor and adjacent tissues were collected for qRT-PCR detection of CDIGPM-related genes.ResultsKaplan-Meier analysis revealed that the high-CDIGPM group exhibited significantly poorer overall survival (OS) trajectories, whereas the low-CDIGPM group showed more favorable OS trajectories, indicating a better prognosis. Age, tumor stage, and CDIGPM score were identified as independent prognostic factors. The high-CDIGPM group was enriched in pathways related to the cell cycle, focal adhesion, and cancer, while the low-CDIGPM group was associated with immune response-related pathways. The CDIGPM model effectively differentiated clinical subtypes in patients with LUAD. QRT-PCR detection of Clinical LUAD samples also validated the differentially expression of CDIGPM model related genes.ConclusionsThe study highlights the prognostic importance of CDIGs in LUAD using the CDIGPM model, linking age, stage and CDIGPM score to poor outcomes. The identified genes and pathways provide potential therapeutic targets, deepening our understanding of LUAD's molecular landscape.

基于 CD8+ T 细胞相关基因特征识别肺腺癌的分子亚型和预后特征
肺腺癌(LUAD)是一种主要的呼吸系统恶性肿瘤,死亡率高。随着免疫疗法的出现,癌症治疗出现了新的治疗途径。目的:本研究旨在建立一种基于CD8+ T细胞的LUAD免疫基因预后模型(CDIGPM),揭示CD8+ T细胞定义的LUAD不同类型的免疫学方面和免疫治疗的潜在优势。方法从TCGA和GEO数据库(GSE11969)中提取LUAD患者的数据。将差异表达基因(deg)与import和InnateDB的免疫基因相交,得到89个与CD8+ T细胞(CDIGs)相关的显著免疫基因。对10个枢纽CDIGs (ADM、CAV1、CTSL、HLA-DMB、HLA-DQA1、IGHM、PLSCR1、PTGDS、S100A16和WFDC2)进行单因素Cox回归和LASSO回归分析。此外,我们还探讨了cdigpm定义类别的免疫学属性和免疫治疗效果。此外,为了支持生物信息学分析的结果,我们收集了15例LUAD患者的肿瘤和邻近组织,进行了cdigpm相关基因的qRT-PCR检测。结果kaplan - meier分析显示,高cdigpm组总生存(OS)轨迹明显较差,而低cdigpm组总生存(OS)轨迹较好,预后较好。年龄、肿瘤分期和CDIGPM评分被确定为独立的预后因素。高cdigpm组富集了与细胞周期、局灶黏附和癌症相关的途径,而低cdigpm组则与免疫反应相关的途径相关。CDIGPM模型能有效区分LUAD患者的临床亚型。临床LUAD样本的QRT-PCR检测也验证了CDIGPM模型相关基因的差异表达。本研究利用CDIGPM模型强调了CDIGPM对LUAD预后的重要性,将年龄、分期和CDIGPM评分与不良预后联系起来。已鉴定的基因和途径提供了潜在的治疗靶点,加深了我们对LUAD分子景观的理解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Biomarkers
Cancer Biomarkers ONCOLOGY-
CiteScore
5.20
自引率
3.20%
发文量
195
审稿时长
3 months
期刊介绍: Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信